Day: August 24, 2021

Increased Tower Ownership and Revenue VANCOUVER, British Columbia, Aug. 24, 2021 (GLOBE NEWSWIRE) — TOWER ONE WIRELESS CORP. (CSE: TO) (OTCQB: TOWTF) (Frankfurt: 1P3N) (“Tower One” or the “Company”) provides a construction update for the month of July 2021. During the month of July, the Company was able to complete eleven (11) new towers and has a total of sixty-six (66) towers under construction in Colombia and Mexico. These towers are built to suit for specific clients and will provide a total, non-cancellable 10 years contracts with 5+ year renewal options, value of $690,000. Tower One began the year with 90 towers in operation and as of July 31st the company now owns and operates 202 towers, given the current construction schedule we expect to have approximately 300 towers in operation by year end.  Construction activity...

TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (“Yamana” or “the Company”) (TSX:YRI; NYSE:AUY; LSE: AUY) today announced that it has repurchased an additional 1,584,500 common shares under the Company’s normal course issuer bid for a cumulative total of 3,321,276 common shares for approximately C$18 million purchased since the initiation of its share repurchase program for up to 5% of the outstanding shares. The Company plans to be selective and opportunistic in relation to share repurchases intending to enter market when permitted and at times when the trading range of its shares do not reflect the underlying value. The Company continues to be committed to further increasing shareholder returns through its capital returns program, and additional share repurchases will be determined based on market conditions, share...

Kering Société anonyme with a capital of € 500,071,664 Head office : 40, rue de Sèvres – 75007 PARIS 552 075 020 RCS PARIS   August 24, 2021   Statement in compliance with article 223-16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des Marchés Financiers)      Date     Total Number of shares   Total number of voting rights  theoretical 1 Exercisable 2  August 15, 2021   125,017,916   177,812,812   177,513,101    1 Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations).   2 Excluding treasury shares stripped of voting rights.  AttachmentKering – Statement Number of Shares and voting rights – 08.15.2021

ATLANTA , Aug. 24, 2021 (GLOBE NEWSWIRE) —WHO: First Advantage (NASDAQ: FA), a leading global provider of technology solutions for screening, verifications, safety and compliance related to human capital   WHAT: Will host a webinar series exploring the state of drug screening.   WHEN: “In the Weeds on Today’s Drug Testing Landscape” will take place on Tuesday, August 31, 2021, at 1:00 p.m. ET.     “The New Future of Drug Screening” will be held on Thursday, September 23, 2021, at 1:00 p.m. ET   WHERE:   To sign up for the August 31 event, click here. To register for the September 23 webinar, click here.DETAILS: According to a June 2021 report from the American Medical Association, COVID-19 has increased drug abuse. Information from health agencies, law enforcement, emergency medical services,...

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients HOUSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate, for an initial Phase 1/ 1b clinical trial that will evaluate the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival...

Verkkokauppa.com Oyj                STOCK EXCHANGE RELEASE         24 August, 2021 at 2:00pm EEST Verkkokauppa.com strengthens its management team to support strategy implementation and business development Verkkokauppa.com Oyj focuses on putting its new strategy into action, refreshes the composition of its management team and appoints a new Chief Strategy and Development Officer. Jyrki Tulokas (KTM) has been appointed Chief Technology Officer of Verkkokauppa.com. Prior to his new position, Jyrki worked at F-Secure in several management positions and has been a member of the management team since 2016, serving as Executive Vice President of Strategy and Business Development, Cyber Security Products and Services, and, most recently, as CTO. In his new role at Verkkokauppa.com, Jyrki will become a member of the management team, reporting...

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that Christina Raaschou joins the Sinch management team as Chief Human Resources Officer. She will assume her role on January 10, 2022. Christina Raaschou has a broad experience of Human Resources and change management with particular focus on international technology organizations. She joins Sinch from a current role at H&M Group, where she is responsible for Human Resources within the global technology organization H&M Group Business Tech. Prior to this, Christina has had leading roles in Human Resources at Unilever and Ericsson and assignments within international recruitment and Executive Search. Sinch’s strategic focus is to drive profitable growth through organic expansion...

PRESS RELEASE Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma FDA grants Priority Review to tebentafusp for the treatment of HLA-A*02:01-positive patients with metastatic uveal melanoma; with an expected Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2022 EMA Committee for Medicinal Products for Human Use accepted tebentafusp Marketing Authorization Application and will review under Accelerated Assessment Procedure (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, August 24, 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR)...